Komatović, K.; Matošević, A.; Terzić-Jovanović, N.; Žunec, S.; Šegan, S.; Zlatović, M.; Maraković, N.; Bosak, A.; Opsenica, D.M.
4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease. Pharmaceutics 2022, 14, 1305.
https://doi.org/10.3390/pharmaceutics14061305
AMA Style
Komatović K, Matošević A, Terzić-Jovanović N, Žunec S, Šegan S, Zlatović M, Maraković N, Bosak A, Opsenica DM.
4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease. Pharmaceutics. 2022; 14(6):1305.
https://doi.org/10.3390/pharmaceutics14061305
Chicago/Turabian Style
Komatović, Katarina, Ana Matošević, Nataša Terzić-Jovanović, Suzana Žunec, Sandra Šegan, Mario Zlatović, Nikola Maraković, Anita Bosak, and Dejan M. Opsenica.
2022. "4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease" Pharmaceutics 14, no. 6: 1305.
https://doi.org/10.3390/pharmaceutics14061305
APA Style
Komatović, K., Matošević, A., Terzić-Jovanović, N., Žunec, S., Šegan, S., Zlatović, M., Maraković, N., Bosak, A., & Opsenica, D. M.
(2022). 4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer’s Disease. Pharmaceutics, 14(6), 1305.
https://doi.org/10.3390/pharmaceutics14061305